» Articles » PMID: 37730567

HAHNet: a Convolutional Neural Network for HER2 Status Classification of Breast Cancer

Overview
Publisher Biomed Central
Specialty Biology
Date 2023 Sep 20
PMID 37730567
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Breast cancer is a significant health issue for women, and human epidermal growth factor receptor-2 (HER2) plays a crucial role as a vital prognostic and predictive factor. The HER2 status is essential for formulating effective treatment plans for breast cancer. However, the assessment of HER2 status using immunohistochemistry (IHC) is time-consuming and costly. Existing computational methods for evaluating HER2 status have limitations and lack sufficient accuracy. Therefore, there is an urgent need for an improved computational method to better assess HER2 status, which holds significant importance in saving lives and alleviating the burden on pathologists.

Results: This paper analyzes the characteristics of histological images of breast cancer and proposes a neural network model named HAHNet that combines multi-scale features with attention mechanisms for HER2 status classification. HAHNet directly classifies the HER2 status from hematoxylin and eosin (H&E) stained histological images, reducing additional costs. It achieves superior performance compared to other computational methods.

Conclusions: According to our experimental results, the proposed HAHNet achieved high performance in classifying the HER2 status of breast cancer using only H&E stained samples. It can be applied in case classification, benefiting the work of pathologists and potentially helping more breast cancer patients.

Citing Articles

AI in Histopathology Explorer for comprehensive analysis of the evolving AI landscape in histopathology.

Ma Y, Jamdade S, Konduri L, Sailem H NPJ Digit Med. 2025; 8(1):156.

PMID: 40074858 PMC: 11904230. DOI: 10.1038/s41746-025-01524-2.


Classifying driver mutations of papillary thyroid carcinoma on whole slide image: an automated workflow applying deep convolutional neural network.

Tsou P, Wu C Front Endocrinol (Lausanne). 2024; 15:1395979.

PMID: 39564124 PMC: 11573888. DOI: 10.3389/fendo.2024.1395979.

References
1.
Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

2.
Yarden Y . Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61 Suppl 2:1-13. DOI: 10.1159/000055396. View

3.
Shovon M, Islam M, Nabil M, Molla M, Jony A, Mridha M . Strategies for Enhancing the Multi-Stage Classification Performances of HER2 Breast Cancer from Hematoxylin and Eosin Images. Diagnostics (Basel). 2022; 12(11). PMC: 9689487. DOI: 10.3390/diagnostics12112825. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Perez E, Romond E, Suman V, Jeong J, Sledge G, Geyer Jr C . Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33):3744-52. PMC: 4226805. DOI: 10.1200/JCO.2014.55.5730. View